Human neurodegenerative diseases—such as Alzheimer’s, Parkinson’s, and Amyotrophic Lateral Sclerosis (ALS)—as well as specific cardiac conditions like dilated cardiomyopathy, are fundamentally driven by proteopathies: the toxic misfolding and accumulation of specific proteins. However, studying these conditions in standard laboratory animals presents a major hurdle. Wild-type rodents and lower vertebrates rarely develop these protein aggregates naturally. Their endogenous proteins possess different amino acid sequences, and their short lifespans mean they do not live long enough to manifest age-dependent protein deposition.
To bridge this gap, researchers design transgenic animal models that express human mutant proteins or replace native animal proteins entirely. By manipulating the genetic architecture of model organisms, scientists can replicate the precise structural folds, post-translational modifications, and downstream cellular cascades required to evaluate human therapeutics.
Replicating Pathogenic Folds via Mutant Overexpression
The most direct way to induce human-like proteopathy in an animal model is the targeted overexpression of human genes carrying familial, disease-causing mutations. Introducing these specific genetic variants accelerates the kinetics of protein misfolding, forcing the animal's cellular machinery to cope with toxic aggregates.
For example, Ana López et al. utilized transgenic zebrafish expressing the rare human A152T tau variant to demonstrate how this specific mutation impairs the proteasome system, triggering widespread neurodegeneration that can be rescued by inducing autophagy. In Parkinson's disease research, Katie K. N. Tran et al. leveraged a transgenic mouse model overexpressing the human A53T $\alpha$-synuclein mutation. This model allowed the authors to establish a direct correlation between $\alpha$-synuclein accumulation in the retina and measurable structural thinning and electrical deficits, offering a non-invasive window into systemic neurodegeneration.
Similarly, in modeling motor neuron diseases like ALS, Julia Post et al. relied on transgenic mice expressing the human $SOD1^{G93A}$ mutation to replicate progressive motor deficits and neuroinflammation, creating a predictable biological timeline to test therapeutic peptide interventions.
Achieving Structural Fidelity Through Humanized Replacement
While overexpressing human mutant proteins provides a robust phenotype, it can sometimes fail to capture subtle disease mechanisms because the animal's native, endogenous proteins remain present and can interfere with aggregate formation. To solve this, researchers turn to humanized protein replacement—knocking out the animal's native gene and replacing it with the human counterpart.
As Nicholas Sweeney et al. explain, replacing endogenous murine proteins with human variants creates a far more accurate representation of human-specific pathological processes. This is because human protein isoforms exhibit distinct aggregation behaviors that animal counterparts simply cannot replicate.
This structural fidelity is paramount. As reviewed by Michel Goedert et al., cryo-EM insights reveal that different neurodegenerative diseases are defined by highly specific, distinct "folds" of protein filaments. Replicating these exact structural features and their post-translational modifications (PTMs) is essential for creating predictive models. This concept is further demonstrated by Alysa Kasen et al., who showed that generating recombinant tau fibrils that accurately mimic both the core structure and the PTMs of patient-derived tau is crucial, as these modifications directly dictate the seeding capacity and propagation of the pathology in vivo.
Overcoming Lifespan and Anatomical Constraints
Mice and zebrafish are invaluable for high-throughput screening, but their short lifespans and simpler nervous systems limit their ability to model diseases that take decades to develop in humans. To overcome these constraints, the field has expanded in two directions: multi-genetic cross-breeding and large-animal modeling.
Cross-breeding allows researchers to combine distinct pathological features into a single organism to study their synergistic effects. For instance, Luana Cristina Camargo et al. generated a novel transgenic mouse line (TAPS) by cross-breeding a line that produces highly neurotoxic pyroglutamate-modified amyloid-beta ($pEA\beta$) with a line that develops standard amyloid plaques. The resulting hybrid model exhibited accelerated amyloid pathology and more pronounced cognitive decline than either parental line alone.
[Line 1: Pyroglutamate-modified Aβ (pEAβ)] \
--> [TAPS Hybrid Model: Accelerated Plaque
[Line 2: Standard Amyloid Plaques] / Deposition & Severe Cognitive Decline]
When rodent anatomy proves insufficient, researchers move to larger, longer-lived species. Weili Yang et al. demonstrated that overexpressing mutant $\alpha$-synuclein (A53T) in rhesus monkeys causes severe, age-dependent axonal degeneration that is completely absent in shorter-lived rodent models. This difference occurs because the mutant protein interacts with neurofascin, an axonal protein with primate-specific features.
To achieve a better model for ALS, Chunhui Huang et al. developed a transgenic pig model expressing mutant TDP-43. This large-animal model successfully recapitulated human-like motor incoordination, muscle atrophy, and fibrosis, providing a translational platform that closely mirrors human clinical presentation.
A Preclinical Platform for Targeted Therapeutics
Ultimately, the value of these high-fidelity transgenic models lies in their ability to serve as rigorous testing grounds for novel therapeutics. By precisely replicating human pathology, they allow researchers to measure target engagement and cognitive or physiological rescue before moving to clinical trials.
In Alzheimer's research, well-established double-transgenic models like 5xFAD and APP/PS1 are widely used to evaluate compound efficacy. Mengyang Zhang et al. utilized the 5xFAD model to discover how plaque-associated axonal spheroids disrupt neural networks, showing that targeting the lysosomal protein PLD3 could restore network function independent of amyloid removal.
Using these advanced pathological models, Sarah Schemmert et al. demonstrated that eliminating $A\beta$ oligomers with a novel compound could reverse cognitive deficits even when administered to mice with full-blown, advanced pathology.
This translational pipeline extends beyond neurodegeneration; for instance, Xuanding Hei et al. utilized a transgenic mouse model of dilated cardiomyopathy expressing specific genetic mutations to induce ventricular enlargement and reduced contractile function. This allowed the authors to evaluate how targeted therapies regulate mitochondrial quality control in a living, failing heart.
Key Foundational Work
A152T tau allele causes neurodegeneration that can be ameliorated in a zebrafish model by autophagy induction (2017) — contributed 1 concept elements to this direction.
Mutant Alpha-Synuclein Causes Age-Dependent Neuropathology in Monkey Brain (2015) — contributed 1 concept elements to this direction.